Lockheed Martin Corporation (LMT) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LOCKHEED MARTIN CORPORATION (LMT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On July 22, 2025, Lockheed released its second quarter 2025 financial results, reporting sharply lower second-quarter earnings, including $1.6 billion in program losses . The Company disclosed it was forced to recognize $950 million in losses related to its Aeronautics Classified program due to 'design, integration, and test challenges, as well as other performance issues' as well as 'significant changes to its processes and testing approach.'
The Company also reported $570 million in losses on its Canadian Maritime Helicopter Program due in part to providing 'additional mission capabilities, enhanced logistical support, fleet life extension, and revised expectations regarding flight hours.' The Company further reported a $95 million charge related to its Turkish Utility Helicopter Program due to the 'current status of the program.' The Company stated it is in 'ongoing discussion' with its customers regarding a potential 'restructure' of certain contractual terms and conditions.
On this news, Lockheed's stock price fell $49.84, or 10.8%, to close at $410.69 per share on July 22, 2025, thereby injuring investors.
Contact Us To Participate or Learn More:
If you purchased Lockheed securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com
Visit our website at: www.howardsmithlaw.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
Lost Money on Reddit, Inc. (RDDT)? Join Class Action Before August 18, 2025 - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - July 24, 2025) - If you suffered a loss on your Reddit, Inc. (NYSE: RDDT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against Reddit, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between October 29, 2024 and May 20, 2025. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) changes in Google Search's algorithm and features like AI Overview were causing users to stop their query on Google Search; (ii) these algorithm changes were materially different than prior instances of reduced traffic to the Reddit website; (iii) defendants were aware that the increase in the query term "Reddit" on search engines was because users were getting the sought after answer from Google Search without having to go to Reddit, and not because they intended to visit Reddit; (iv) this zero-click search reality was dramatically reducing traffic to Reddit in a manner the Company was unable to overcome in the short term; (v) defendants, therefore, lacked a reasonable basis for their outlook on user rates and advertising revenues; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in Reddit, Inc. stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
Globe and Mail
33 minutes ago
- Globe and Mail
CRH Announces Date for Q2 2025 Results Conference Call
CRH (NYSE: CRH), the leading provider of building materials solutions, will publish its Q2 2025 financial results after market close on Wednesday, August 6, 2025 followed by a conference call and webcast presentation at 8:00 a.m. (EDT) on Thursday, August 7, 2025. CRH's results and the related presentation will be available at Registration for the event can be made at Upon registration a link to join the call and dial-in details will be made available. A replay of the webcast will be available on About CRH CRH (NYSE: CRH) is the leading provider of building materials solutions that build, connect and improve our world. Employing 80,000 people at over 3,800 operating locations in 28 countries, CRH has market leadership positions in North America and Europe. As the essential partner for transportation and critical infrastructure projects, complex non-residential construction and outdoor living solutions, CRH's unique offering of materials, products and value-added services helps to deliver a more resilient and sustainable built environment. The company is ranked among sector leaders by Environmental, Social and Governance (ESG) rating agencies. A Fortune Global 500 company, CRH's shares are listed on the NYSE and LSE.
National Post
35 minutes ago
- National Post
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk--Long Before the Clinic
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENS ai ™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. Article content 'ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,' said Dr. Jennifer Bath, President & CEO, IPA. 'With LENS ai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.' Article content Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic 'self/non‑self' checks largely unaddressed. Article content LENS ai 's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome 'humanness' scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Article content Study Highlights Article content 217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. Detailed amino acid and epitope-level immunogenicity 'self' scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. Article content Read the full case study: Article content [ Article content link Article content ] Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Article content Forward-Looking Statements Article content This press release contains forward looking statements within the meaning of applicable United States and Canadian securities laws. Forward looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' 'potential,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. Examples include statements regarding the projected performance, scalability, and market adoption of the Company's LENSai™ Immunogenicity Screening; the ability of its HYFT® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ADA prediction on biopharma R&D efficiency; and the Company's broader scientific, commercial, and capital markets objectives. Article content Forward looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results could differ materially from those expressed or implied because of factors beyond the Company's control, including the pace of scientific and technological innovation in AI driven drug discovery, the accuracy and regulatory acceptance of in-silico ADA risk screening, competitive shifts as the industry transitions away from MS dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. Additional information about these and other risks and uncertainties is set out in the Company's Annual Report on Form 20F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at If any of these risks materialize, the Company's actual results, performance, or achievements could vary significantly from those currently anticipated. Article content Article content Article content Article content Contacts Article content Investor Relations Contact Article content Article content Article content Article content
